Check out the companies making headlines in extended trading: Palantir Technologies — Shares dropped nearly 7% after the defense tech company reported first-quarter earnings that were in line with Wall Street’s expectations. Adjusted earnings of 13 cents per share came in line with the consensus estimate, per LSEG. Palantir reported $884 million in revenue, topping the $863 million forecast by analysts. Vertex Pharmaceuticals — The biotech stock dropped 2% on disappointing quarterly results. Adjusted earnings came in at $4.06 per share, below the $4.32 per share forecast by analysts surveyed by LSEG. Revenue of $2.77 billion also missed analysts’ estimates for $2.85 billion. Mattel — Shares of the toymaker declined 2.5% after management paused its 2025 full-year guidance due to tariff uncertainty. Meanwhile, first-quarter results topped analysts’ estimates. Neurocrine Biosciences — The maker of neurological drugs jumped 11% postmarket after first-quarter revenue of $572.6 million topped a $559.6 million estimate from analysts surveyed by FactSet. Sales of Ingrezza, used to treat movement disorders, rose 8% year over year to $545 million. Lattice Semiconductor — The chip stock fell 3.8% after first-quarter earnings and revenue both were in line with consensus estimates. Lattice guided toward current-quarter revenue between $118.5 million and $128.5 million, while analysts polled by LSEG expected $123.6 million. Adjusted earnings are estimated to range betwe …
